Loading clinical trials...
Loading clinical trials...
The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an oral glucose tolerance test
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Massachusetts General Hospital
Collaborators
NCT07547098 · Cardiovascular Diseases (CVD), Chronic Kidney Disease, and more
NCT06672237 · Neuromuscular Disease, Neuromuscular Diseases (NMD), and more
NCT06003153 · Genetic Predisposition, Metabolic Diseases, and more
NCT06593327 · Type 2 Diabetes, Diabetic Cardiomyopathy, and more
NCT07420023 · Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease
Massachusetts General Hospital
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions